Phathom Pharmaceuticals, Inc. (PHAT)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Phathom Pharmaceuticals, Inc. (“Phathom” or “the Company”) (NASDAQ: PHAT). Investors who purchased Phathom shares are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Phathom violated federal securities laws.
On August 2, 2022, Phathom issued a press release titled: “Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates,” which announced that “we detected trace levels of a nitrosamine in vonoprazan drug product in our post-approval testing as we prepared for commercial launch.” The release continues that based on this detection, “the Company is working with the FDA and plans to obtain approval of and implement an additional test method, specification, including a proposed acceptable intake limit, and additional controls to address this impurity prior to releasing our first vonoprazan-based products to the market.” Phathom said that “these additional activities will result in a delay of the planned VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK product launches.” Following this news, Phathom stock dropped almost 29% on that same day.
If you are aware of any facts relating to this investigation or purchased Phathom shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.